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Hyperbaric oxygen therapy (HBOT) has enhanced the prevention and treatment of auditory 
ailments such as ototoxicity.
Objective: To study the effects of HBOT upon ototoxic injuries produced by amikacin.
Method: This experimental study included 12 albino guinea pigs, whose auditory function was 
assessed through distortion product otoacoustic emissions (DPOAEs) and brainstem auditory evoked 
potentials (BAEPs) before and after the administration of amikacin (600 mg/kg/day) and HBOT 
sessions (2 ATA, 60 minutes). Morphological features were analyzed through scanning electron 
microscopy. Subjects were divided into four groups, as follows: group 1 - saline solution + HBOT; 
group 2 - amikacin for 8 days; group 3 - amikacin + seven days of rest; and group 4 - amikacin + 
HBOT.
Results: Group 1 subjects had preserved function and morphology throughout the experiment; group 
2 subjects had statistically significant levels of hair cell injury and functional impairment; subjects on 
groups 3 and 4 had statistically significant functional and morphological impairment after the admin-
istration of amikacin, which were still present after the proposed procedures had been carried out.
Conclusion: Hyperbaric oxygen therapy did not change the cochlear hair cell morphology or the 
electro-physiological thresholds of the guinea pigs given amikacin.
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INTRODUCTION
A wide range of drugs may produce transient or 
permanent auditory and vestibular impairment as side 
effects, in what is referred to as drug-related ototoxicity1. 
Aminoglycosides are included in this group of drugs, 
and are commonly used in the treatment of infectious 
diseases because of their effectiveness and affordability. 
Among them, amikacin has an estimated rate of ototoxic 
events of 13.9%2.
Amikacin is used more specifically in pediatric 
patients3,4 with therapeutic and prophylactic purposes, 
and is broadly prescribed to treat sepsis, meningitis, 
bacteremia5, urinary6 and respiratory7,8 tract infections. 
Amikacin has been correlated with decreased perinatal 
mortality and increased survival in pediatric patients. 
However, patients are at a significantly higher risk for 
side effects such as hearing loss4.
Experimental studies have shown that intramus-
cular amikacin at a dosage of 400 mg/kg/day obliterates 
outer hair cells (OHC) and partially injures inner hair 
cells (IHC)9,10.
On the other hand, hyperbaric oxygen therapy 
(HBOT), in which individuals are placed in a hyper-
baric chamber breathing 100% oxygen at pressures 
higher than normal atmospheric pressure (between 
two and three atmosphere absolutes - ATA)11, has 
shown favorable effects for various diseases. Research 
in the areas of otorhinolaryngology and audiology 
have resorted to hyperbaric medicine, particularly 
HBOT, as a means to prevent and treat conditions 
such as sudden deafness12-14, noise-induced hearing 
loss15, and ototoxicity16.
This study aimed to contribute to the under-
standing of the inner ear pathophysiological protection 
mechanisms acting against drug-induced ototoxicity and 
more specifically the impact of HBOT upon ototoxic 
injuries introduced by amikacin.
METHOD
This experimental clinical trial was approved by 
the Ethics Committee and was granted permits 035/2011 
and 407/10. The animals included in the study were male 
albino guinea pigs (Cavia porcellus) of the English strain, 
weighing approximately 400 grams, selected based on 
Preyer’s reflex.
The sample
The study included 24 cochleas from 12 guinea 
pigs. The subjects underwent examination for distortion 
product otoacoustic emissions (DPOAE) and brain-
stem auditory evoked potentials (BAEP) under anes-
thesia with intramuscular ketamine hydrochloride (40 
mg/kg) and xylazine (10 mg/kg). Included subjects 
had to have DPOAEs and BAEPs. Guinea pigs with 
otitis, ear wax, and narrow ear canals that prevented 
the placement of an auditory catheter were excluded. 
The subjects were divided into four groups:
•	 Group 1: Three guinea pigs (six cochleas) 
were given subcutaneous saline solution for 
eight days. Forty-eight hours after the last 
injection they were submitted to three ses-
sions of HBOT (two ATA for 60 minutes) on 
days 11, 13, and 15 of the experiment.
•	 Group 2: Three guinea pigs (six cochleas) 
were administered subcutaneous amikacin 
(600 mg/kg/day) for eight consecutive days.
•	 Group 3: Three guinea pigs (six cochleas) 
were administered subcutaneous amikacin 
(600 mg/kg/day) for eight consecutive days. 
They rested for another seven days and were 
given subcutaneous saline solution.
•	 Group 4: Three guinea pigs (six cochleas) 
were administered subcutaneous amikacin 
(600 mg/kg/day) for eight consecutive days. 
Forty-eight hours after the last injection they 
were submitted to three sessions of HBOT 
(two ATA for 60 minutes) on days 11, 13, and 
15 of the experiment.
Auditory function assessment
Auditory function assessment was based on 
DPOAEs and BAEPs. The devices used were the SMART 
DPOEA® and the SMART EP® from Intelligent Hearing 
Systems - Miami/Florida (USA).
Auditory function tests were carried out in the 
beginning of the experiment (in all groups), before 
HBOT sessions (groups one and four), before resting 
(group three), and immediately before the subjects were 
slaughtered (in all groups).
DPOAE tests followed the list of frequencies 2F(1) - 
F(2) at a ratio F(1)/F(2) = 1.22. Otoacoustic emissions 
starting at 1.5 kHz were considered. The size of the ear 
canals of the guinea pigs prevented emissions under 
this frequency from being assessed, as responses could 
be mistaken for noise10. As described by other authors, 
the intensity used in this study was 70 dB NPS for F(1) 
and F(2)2,16,17.
The hair in the vertex area and in the region 
between the orbits was shaved to aid in BAEP capture. 
The posterior portion of the pinna was cleaned with 
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a steel sponge to remove oil and improve the contact 
between the electrode and the skin18. Surface electrodes 
were placed as follows: one positive electrode on the 
cranial vertex, two negative electrodes on the poste-
rior portion of the pinna, and the ground wire on the 
forehead of the subjects, between their orbits. A layer 
of electrolytic paste was placed between the tip of the 
electrodes and the skin of the subjects to improve the 
conduction of the electric signals18.
Insertion earbuds were used to convey the sound 
stimuli. Alternated clicks of 0.1 ms were played at a 
rate of 27.7 stimuli per second. Fundamental frequency 
was 1,000 Hz at an intensity of 90 dB nHL. The signal 
captured by the electrodes was submitted to high pass 
and low pass filters of 150 Hz and 3,000 Hz respecti-
vely. Filtered amplified signals had their mean values 
calculated based on 1024 scans of BAEP records with a 
12 ms window. The result was provided in the form of 
electric potential waves18. Only wave I was considered 
in this study, as it recorded the potential of the auditory 
nerve and is part of the peripheral auditory system18. 
Electrophysiological thresholds were calculated as sound 
stimuli were played in decreasing steps of 10 dB down 
to the approximated threshold.
Hyperbaric oxygen therapy procedure
HBOT sessions were carried in the Department 
of Experimental Surgery in a small-size multiple-subject 
experimental hyperbaric chamber. Three sessions were 
held in alternating days15. Each session lasted 100 
minutes at 2 ATA, sixty minutes of which at absolute 
pressure15.
Preparation for scanning electron microscopy (SEM)
The guinea pigs were anesthetized as per the 
protocol and slaughtered at the end of the observation 
period by decapitation19.
The bulla tympani was opened and 2.5% gluta-
raldehyde slowly injected through an opening made 
in the apex of the cochlea and the round window; 
the specimens were immersed in this solution for four 
hours at 4°C9,15,17-20. After fixation in glutaraldehyde, 
the specimens were washed five times18 in 0.1 M 
phosphate buffer solution and dissected to expose 
the cochlear turns9,15,17-20. After washing, the cochleas 
were fixated once again in 1% osmium tetroxide and 
0.1 M phosphate buffer solution for two hours at 
4°C, and washed in 0.1 M phosphate buffer solution 
at a pH of 7.39,15,17-20. The specimens were dipped in 
ethanol in growing concentrations of 50%, 70%, 90%, 
and 95% for 10 minutes each to be dehydrated. Then 
they were dipped in 100% ethanol in three cycles of 
20 minutes each, and in one last cycle of 12 hours in 
ambient temperature9,15,17-20. The water still present in 
the specimens after dehydration was removed through 
the carbon dioxide critical point drying method. A 
BAL-TEC CPD 030® (Critical Point Dryer) was used in 
the drying process. The ethanol in the specimens was 
removed by dipping them in carbon dioxide at 4°C; 
then the specimens were heated to 40°C to remove 
the carbon dioxide by evaporation, which happened 
at 31°C - the critical point9,15,17-20.
The dry specimens were mounted and glued to 
cylindrical metal stubs using carbon conduction paste9,17. 
In order to allow proper analysis and observation of 
structures on SEM, the cochleas were covered by a thin 
layer of gold using a BAL-TEC SCD 050 device. After 
preparation, the cochleas were electrically conductive 
for SEM9,16,17.
Criteria for SEM
SEM images were analyzed for OHC counts in the 
basal, T2 and T3 turns of the cochlea and for presence, 
absence, or partial presence of inner hair cells in all 
turns of the cochlea and of outer hair cells in the apical 
turn of the cochlea.
Statistical analysis
The Friedman and the Wilcoxon tests were used 
to assess the differences between DPOAEs. Both tests 
were used because the study entailed random variables 
from the same subjects that changed with time. The 
tests were performed considering a significance level of 
95%. The Friedman test was used to assess BAEPs with 
a significance level of 95%. Each cochlea represented 
a different, independent experiment, which reflected 
the temporal evolution of each cochlea. Morphological 
data was treated using the Kruskal-Wallis test with a 
significance level of 95%. This analysis considered each 
different turn of the cochlea, namely the basal, T2, T3, 
and apical turns, and analyzed them separately. The 
effects of amikacin and the offered procedures (HBOT 
and rest) were considered in each case.
Statistical analysis was performed using Microsoft 
Excel® and software package EXStat® for non-parametric 
tests21.
RESULTS
DPOAE assessment showed absence of responses 
in all groups given amikacin as they were tested after 
eight consecutive days of drug administration. The 
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Wilcoxon test revealed a statistically significant diffe-
rence between mean signal-to-noise (SNR) ratios before 
and after amikacin administration (p ≤ 0.01).
The DPOAEs of the guinea pigs in groups three 
and four were absent after eight days of amikacin ad-
ministration and were still absent and with reduced 
SNR in both groups after they were submitted to the 
proposed procedures. Significant differences (p ≤ 0.05) 
were observed in mean SNR after amikacin and after 
rest or HBOT.
Group 1 had present DPOAEs before and after 
HBOT. The Wilcoxon test (p ≥ 0.05) indicated absence 
of a significant difference in the subjects’ DPOAEs.
In BAEP testing, the electrophysiological threshol-
ds were increased in groups 2, 3, and 4 after the admi-
nistration of amikacin and after HBOT or rest. The Frie-
dman test (p ≤ 0.05) showed that pre and post-amikacin 
administration records were statistically different. After 
amikacin administration, all guinea pigs had electrophy-
siological thresholds above 90 dB nHL and significant 
hearing loss.
The study’s results showed that the subjects had 
preserved peripheral auditory systems before the expe-
riment and that these structures were altered and they 
had hearing loss after the administration of amikacin. 
Hearing loss was still present after the end of the expe-
riment, regardless of the procedure they were offered 
after amikacin administration (rest or HBOT).
Group 1 subjects had unaltered thresholds. The 
Friedman test yielded a p-value = 1, showing that the 
samples were identical in terms of BAEPs.
Morphological assessment through SEM revealed 
significant injuries to OHC and IHC in all turns of the 
cochlea (Figure 1). Inner hair cells of the basal turn were 
less affected in the groups given amikacin.
In group 4, OHC and IHC injuries were seen 
after eight days of amikacin administration and after 
HBOT, without significant gains in terms of morphology 
(Figure 2). Similar results were seen in group 3. IHC and 
OHC morphology was not altered in group 1, and the 
three rows of outer hair cells and the row of inner hair 
cells were preserved (Figure 3).
The Kruskal-Wallis test yielded a p-value = 0.5 
when OHC counts of the basal, T2, T3, and apical turns 
of the cochlea for guinea pigs given amikacin minus 
subjects on group 1 were considered. IHC counts of the 
basal, T2, T3, and apical turns of the cochlea for guinea 
pigs given amikacin yielded a p-value = 0.22. In both 
cases, the hypothesis of the groups being statistically 
similar was rejected.
Figure 1. Basal turn of the cochlea of a guinea pig in group 2 showing 
OHC involvement in all rows and IHC injury (SEM - 1,000x).
Figure 2. Basal turn of the cochlea of a guinea pig in group 4 showing 
OHC involvement in all rows and IHC injury (SEM - 1,000x).
Figure 3. T2 of the cochlea of a guinea pig in group 1 with preserved 
OHC and IHC. IHC: F1: row 1; F2: row 2; F3: row 3 (SEM - 1,000x).
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The morphology of outer and inner hair cells were 
not altered in group 1 subjects, and all hair cell rows 
were preserved (Figure 3).
DISCUSSION
Amikacin is broadly used to treat infectious 
diseases, particularly in pediatric patients, and has been 
correlated to significant ototoxicity and irreversible 
auditory injury. Patients affected by ototoxicity are forced 
to deal with hearing loss and the socioeconomic barriers 
imposed by it. The significant costs of rehabilitating 
these individuals and procuring the usually imported 
hearing aids must be considered from the point of view 
of public health.
According to the medical literature, aminoglycosides 
may be detected in the perilymph 60 to 90 minutes and 
in hair cells three to four months after systemic drug 
administration22. The adoption of measures to abolish 
or diminish drug deleterious effects is a challenge to 
be considered.
Hyperbaric oxygen therapy (HBOT)
HBOT has been effectively used in other contexts 
to treat sudden deafness13 and offer protection against 
noise-induced auditory injuries15 and ototoxicity by 
cisplatin16.
The auditory protection provided by HBOT 
has not been clearly described. However, one of the 
mechanisms involved in amikacin ototoxicity may be 
related to hair cell ischemia and excessive production 
of oxygen reactive species accompanied by the typically 
associated injuries.
HBOT reportedly improves oxidative stress by 
increasing the production of antioxidants and antio-
xidant enzymes such as glutathione and superoxide 
dismutase (SOD), in addition to reducing the levels of 
markers of oxidative stress such as malondialdehyde 
and consequently promoting auditory protection by 
eliminating the oxygen reactive species produced by 
amikacin.
This study looked into the effects of HBOT upon 
ototoxic injuries introduced by amikacin to further the 
understanding of the pathophysiological mechanisms 
related to inner ear protection.
Ototoxicity was analyzed based on two parameters: 
morphology and function.
Morphology
Studies on ototoxicity have routinely resorted to 
SEM to assess hair cell morphology9,10,15,17,19,23.
The data gathered in this study suggest that the 
subcutaneous administration of amikacin introduced 
morphologic alterations in the cochleas of the included 
guinea pigs. HBOT did not offer any protection against 
cochlear damage.
Function
DPOAEs have been effectively used to assess 
OHC function15,16,23.
The functional findings related to amikacin oto-
toxicity reported in this study were in agreement with 
the findings published in other studies9,10,17.
Authors studying ultrastructural and functional 
cochlear alterations in animal models found extensive 
OHC lesions after systemic administration of amikacin 
for 12 consecutive days. These findings were supported 
by this study and corroborate the ototoxic potential of 
amikacin10.
The guinea pigs treated with amikacin and submit-
ted to HBOT did not have DPOAEs after eight days of 
drug treatment and had reduced SNR at the end of the 
experiment, revealing a possible deterioration of OHC 
function. These findings were also seen in the group 
submitted to rest after amikacin administration.
Authors have suggested that the degree of DPOAE 
impairment seen in patients on aminoglycosides is 
directly correlated to the length of treatment4,24,25.
Based on the literature, one may assume that such 
functional deterioration could be the outcome of the 
cumulative effect of amikacin, as these findings were 
seen in the rest and HBOT groups.
Wave I thresholds were increased (> 90 dB nHL) 
in all groups given amikacin and remained altered after 
HBOT. Similar findings were seen in the rest group. 
Neither of the procedures produced statistically signifi-
cant improvements, as supported by the morphologic 
findings seen in the subjects.
DPOAEs may be present in subjects with hea-
ring loss of up to 50 dB NA26. The data gathered in 
this study, in which DPOAEs were absent, match the 
BAEP findings and show the devastating effects of 
the administered dosage of amikacin as reported in 
the literature on aminoglycoside-induced ototoxici-
ty4,9,10,17,27-29.
This study failed to show the auditory protective 
effects of HBOT reported in the literature16; in the cited 
paper, the authors used intraperitoneal injections of 
cisplatin (8 mg/kg/day) administered for three conse-
cutive days to induce ototoxicity, submitted the inclu-
ded guinea pigs to HBOT, and reported morphologic 
and functional improvements in the subjects’ outer 
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hair cells. The number of animals used in this study is 
consistent with the literature9,10,15,16 and was based on 
the recommendations of the Research Ethics Committee; 
the differences found in our study cannot be attributed 
to this variable. However, it is possible that differences 
in metabolic pathways and modes of injury may have 
had a determining role.
Closing remarks
The hyperoxia caused by HBOT increases tissue 
tolerance to ischemia and enhances the biologic res-
ponse against oxygen reactive species. Future studies 
with similar methodology should consider different 
times of exposure to the same dosages of amikacin 
and the same HBOT protocol described in this study. 
Oxidative stress improvements secondary to HBOT 
by increases in the production of antioxidants and 
antioxidant enzymes such as glutathione and supero-
xide dismutase could be more thoroughly assessed, as 
well as reductions in oxidative stress markers such as 
malondialdehyde.
CONCLUSION
•	 HBOT did not lead to significant improve-
ments in the morphology of the hair cells 
exposed to amikacin.
•	 The electrophysiological thresholds of the 
guinea pigs given amikacin were not signifi-
cantly improved after HBOT, and remained 
equal to or greater than 90 dB nHL.
•	 HBOT did not improve the outer hair cell 
function of the guinea pigs given subcuta-
neous amikacin.
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